What this means
This trial is testing whether a daily vitamin B3 pill slows Huntington's disease in adults. It has not finished, and no results have been posted yet, so we do not know if it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–80
- Where
- 1 site
The science
- Registered title
- The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
- Trial ID
- NCT06853743 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Huntington Disease
- What is tested
- Nicotinamide Riboside (NR), Placebo
- Sponsor
- Oslo University Hospital
- Ages
- 18 Years to 80 Years
- Dates
- First posted Mar 3, 2025 · updated Mar 19, 2025
Registry summary
The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease. It will also learn about the safety of nicotinamide riboside. The main questions it aims to answer are:
- Does NR slow progression of overall symptom burden in Huntington's disease?
- Does NR have an effect on any specific symptom domain in Huntington's disease?
- Does supplementation with NR cause side-effects or safety issues when used for 2 years in Huntington's disease?
- Does NR have an effect on selected blood, imaging, and oculomotor biomarkers in Huntington's disease?
Researchers will compare NR to a placebo (a look-alike substance that contains no active compound) to see if NR works to treat Huntington's disease.
Participants will:
- Take 2000mg NR or a placebo every day for 2 years
- Visit the clinic once every 6 months for clinical investigations and tests
- Undergo brain imaging at baseline and upon completion of the study period
Sites (1)
- Oslo University Hospital, Oslo, Norway